209 related articles for article (PubMed ID: 24942307)
1. Uric acid as a cardiorenal risk factor - ready for prime-time?
Patel KH; Goldsmith DJ
Int J Clin Pract; 2014 Jul; 68(7):796-801. PubMed ID: 24942307
[TBL] [Abstract][Full Text] [Related]
2. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
Sánchez-Lozada LG; Tapia E; Soto V; Avila-Casado C; Franco M; Zhao L; Johnson RJ
Nephrol Dial Transplant; 2008 Apr; 23(4):1179-85. PubMed ID: 18048425
[TBL] [Abstract][Full Text] [Related]
3. Time to target uric acid to retard CKD progression.
Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
[TBL] [Abstract][Full Text] [Related]
4. Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid.
Hirai T; Kimura T; Echizen H
Biol Pharm Bull; 2016; 39(6):1013-21. PubMed ID: 27251504
[TBL] [Abstract][Full Text] [Related]
5. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
6. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
Mallat SG; Al Kattar S; Tanios BY; Jurjus A
Curr Hypertens Rep; 2016 Oct; 18(10):74. PubMed ID: 27696189
[TBL] [Abstract][Full Text] [Related]
7. Febuxostat for prevention of gout attacks.
Pohar S; Murphy G
Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
[TBL] [Abstract][Full Text] [Related]
8. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
[TBL] [Abstract][Full Text] [Related]
9. Febuxostat--treatment for hyperuricemia and gout?
Moreland LW
N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
[No Abstract] [Full Text] [Related]
10. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
11. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
Whelton A; MacDonald PA; Chefo S; Gunawardhana L
Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
[TBL] [Abstract][Full Text] [Related]
12. Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Uchida S; Kumagai T; Chang WX; Tamura Y; Shibata S
Contrib Nephrol; 2018; 192():56-68. PubMed ID: 29393121
[TBL] [Abstract][Full Text] [Related]
13. [HYPERURICEMIA AND POTENTIAL RISK OF CARDIOVASCULAR AND RENAL DISEASES].
Schils R; Krzesinski JM
Rev Med Liege; 2016 May; 71(5):262-8. PubMed ID: 27337847
[TBL] [Abstract][Full Text] [Related]
14. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
[TBL] [Abstract][Full Text] [Related]
15. A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
Kamatani N; Hosoya T
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S11-2. PubMed ID: 21654264
[No Abstract] [Full Text] [Related]
16. Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia.
Ohta Y; Ishizuka A; Arima H; Hayashi S; Iwashima Y; Kishida M; Yoshihara F; Nakamura S; Kawano Y
Hypertens Res; 2017 Mar; 40(3):259-263. PubMed ID: 27760998
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular and renal effects of hyperuricaemia and gout.
Viazzi F; Leoncini G; Pontremoli R
Reumatismo; 2012 Jan; 63(4):253-62. PubMed ID: 22303532
[TBL] [Abstract][Full Text] [Related]
18. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor?
Nashar K; Fried LF
Adv Chronic Kidney Dis; 2012 Nov; 19(6):386-91. PubMed ID: 23089273
[TBL] [Abstract][Full Text] [Related]
19. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition.
Harzand A; Tamariz L; Hare JM
Congest Heart Fail; 2012; 18(3):179-82. PubMed ID: 22587748
[TBL] [Abstract][Full Text] [Related]
20. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
Bove M; Cicero AF; Veronesi M; Borghi C
Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
